Adherence to medical recommendations and transition to adult services in pediatric transplant recipients.
OBJECTIVE
Nonadherence to treatment recommendations, especially when associated with transition to adult care providers, account, by some estimates, for most organ rejections and death in long-term pediatric survivors of solid organ transplantations. It is therefore imperative that providers become familiar with the issues related to those major risks and ways to address them.


RESULTS
It is possible, and important, to routinely measure adherence to medications by using one of several available and proven methods of surveillance. There are numerous ways to improve adherence, and it is in fact possible to improve adherence and therefore outcomes in the transplant setting. The transition to adult services is a vulnerable period. The authors believe that it is possible to improve the transition process, and suggestions are presented in this review. However, solid research into interventions to improve transition is lacking.


CONCLUSIONS
Nonadherence to medical recommendations is prevalent and leads to poor outcomes following otherwise successful pediatric transplantation. An especially vulnerable period is the time when a recipient transitions to adult care. Routine monitoring of adherence, evaluating and addressing barriers to adherence, and collaborative, multidisciplinary care are all expected to substantially improve adherence and reduce the risks associated with transition.
Shemesh
Eyal
E
Division of Developmental and Behavioral Health, Department of Pediatrics and The Kravis Children's Hospital, New York 10029, USA. eyal.shemesh@mssm.edu
Annunziato
Rachel A
RA
Arnon
Ronen
R
Miloh
Tamir
T
Kerkar
Nanda
N
D000293:Adolescent; D000328:Adult; D003266:Continuity of Patient Care; D016903:Drug Monitoring; D006084:Graft Rejection / Q000209:etiology / Q000517:prevention & control*; D006085:Graft Survival; D015438:Health Behavior; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D055118:Medication Adherence; D016377:Organ Transplantation / Q000009:adverse effects; D010353:Patient Education as Topic; D017410:Practice Guidelines as Topic; D018570:Risk Assessment; D012307:Risk Factors; D016896:Treatment Outcome; D055815:Young Adult
D007166:Immunosuppressive Agents
Pediatr Nephrol. 2000 Jun;14(6):469-72
10872185
Intern Med J. 2007 Aug;37(8):555-60
17640188
Pediatr Nephrol. 1997 Oct;11(5):547-51
9323277
J Pediatr Psychol. 2011 Mar;36(2):155-9
19995864
J Cardiovasc Nurs. 2005 Sep-Oct;20(5 Suppl):S88-98
16160588
Pediatr Transplant. 2005 Jun;9(3):381-90
15910397
Pediatr Transplant. 2000 Aug;4(3):200-6
10933320
Am J Transplant. 2003 Nov;3(11):1418-25
14525604
Pediatrics. 2009 Nov;124(5):e844-50
19822583
Med J Aust. 2005 Oct 17;183(8):405-9
16225444
Pediatr Transplant. 2004 Dec;8(6):600-5
15598333
Pediatrics. 2004 Apr;113(4):825-32
15060234
J Am Acad Child Adolesc Psychiatry. 2007 Oct;46(10):1280-1289
17885569
J Pediatr Gastroenterol Nutr. 2006 Nov;43(5):629-34
17130740
Pediatr Transplant. 2002 Dec;6(6):493-9
12453202
Cancer. 2006 Oct 1;107(7 Suppl):1702-9
16921480
Annu Rev Med. 1997;48:283-93
9046962
Pediatr Transplant. 2008 May;12(3):316-23
18435607
Pediatr Transplant. 2008 Feb;12(1):67-72
18186891
Pediatr Transplant. 2008 May;12(3):281-3
18331535
Pediatr Transplant. 2008 May;12(3):284-8
18331387
Pediatr Transplant. 2007 Jun;11(4):422-8
17493224
Diabet Med. 2002 Aug;19(8):649-54
12147145
Am J Health Syst Pharm. 2008 Jul 1;65(13):1242-7
18574014
Child Health Care. 1989 Fall;18(4):218-24
10296097
Pediatr Transplant. 2007 Sep;11(6):608-14
17663682
Pediatrics. 2004 Mar;113(3 Pt 1):e197-205
14993577